3/18
07:00 am
eypt
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Low
Report
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3/9
08:48 am
eypt
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Analysts Just Slashed This Year's Revenue Estimates By 22% [Yahoo! Finance]
Medium
Report
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Analysts Just Slashed This Year's Revenue Estimates By 22% [Yahoo! Finance]
3/8
09:47 am
eypt
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/8
05:52 am
eypt
EyePoint Pharmaceuticals Full Year 2023 Earnings: Beats Expectations [Yahoo! Finance]
Medium
Report
EyePoint Pharmaceuticals Full Year 2023 Earnings: Beats Expectations [Yahoo! Finance]
3/7
01:39 pm
eypt
EyePoint Pharmaceuticals Inc (EYPT) Reports Growth Amidst Strategic Shifts in Q4 and Full-Year 2023 [Yahoo! Finance]
Low
Report
EyePoint Pharmaceuticals Inc (EYPT) Reports Growth Amidst Strategic Shifts in Q4 and Full-Year 2023 [Yahoo! Finance]
3/7
10:50 am
eypt
Compared to Estimates, EyePoint Pharmaceuticals (EYPT) Q4 Earnings: A Look at Key Metrics [Yahoo! Finance]
Low
Report
Compared to Estimates, EyePoint Pharmaceuticals (EYPT) Q4 Earnings: A Look at Key Metrics [Yahoo! Finance]
3/7
07:16 am
eypt
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments [Yahoo! Finance]
Medium
Report
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments [Yahoo! Finance]
3/7
07:00 am
eypt
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
Medium
Report
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
3/4
07:17 am
eypt
EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer [Yahoo! Finance]
Medium
Report
EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer [Yahoo! Finance]
3/4
07:00 am
eypt
EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer
Medium
Report
EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer
2/29
07:23 am
eypt
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024 [Yahoo! Finance]
Low
Report
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024 [Yahoo! Finance]
2/29
07:00 am
eypt
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024
Low
Report
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024
2/27
07:12 am
eypt
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences [Yahoo! Finance]
2/27
07:00 am
eypt
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Medium
Report
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
2/22
06:44 am
eypt
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "overweight" rating re-affirmed by analysts at Capital One Financial Co..
Low
Report
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "overweight" rating re-affirmed by analysts at Capital One Financial Co..
2/19
08:50 pm
eypt
Review Of The Developmental Landscape Of Long-Acting Anti-VEGF Therapies In Wet-AMD [Seeking Alpha]
Medium
Report
Review Of The Developmental Landscape Of Long-Acting Anti-VEGF Therapies In Wet-AMD [Seeking Alpha]
2/16
07:34 pm
eypt
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target raised by analysts at Mizuho from $30.00 to $39.00. They now have a "buy" rating on the stock.
Medium
Report
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target raised by analysts at Mizuho from $30.00 to $39.00. They now have a "buy" rating on the stock.
2/16
07:00 am
eypt
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Low
Report
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2/3
04:26 pm
eypt
EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration [Yahoo! Finance]
Low
Report
EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration [Yahoo! Finance]
2/3
04:20 pm
eypt
EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration
Low
Report
EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration
1/31
07:12 am
eypt
EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference [Yahoo! Finance]
Medium
Report
EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference [Yahoo! Finance]
1/31
07:00 am
eypt
EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Medium
Report
EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
1/29
11:12 pm
eypt
EyePoint Pharmaceuticals Inc SVP & Chief Commercial Officer David Jones Sells 26,017 Shares [Yahoo! Finance]
Medium
Report
EyePoint Pharmaceuticals Inc SVP & Chief Commercial Officer David Jones Sells 26,017 Shares [Yahoo! Finance]
1/26
12:10 am
eypt
EyePoint Pharmaceuticals Inc's Chief Medical Officer Dario Paggiarino Sells 16,386 Shares [Yahoo! Finance]
Medium
Report
EyePoint Pharmaceuticals Inc's Chief Medical Officer Dario Paggiarino Sells 16,386 Shares [Yahoo! Finance]
1/24
07:13 pm
eypt
EyePoint Pharmaceuticals Inc SVP & Chief Commercial Officer David Jones Sells 35,066 Shares [Yahoo! Finance]
Low
Report
EyePoint Pharmaceuticals Inc SVP & Chief Commercial Officer David Jones Sells 35,066 Shares [Yahoo! Finance]